medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2017, Number 1

<< Back

VacciMonitor 2017; 26 (1)

Products development management in the biotechnological industry

Ledón-Naranjo N, Castillo-Vitlloch A, Caballero-Torres I, Lage-Dávila A

Language: Spanish
References: 33
Page: 31-43
PDF size: 208.92 Kb.


ABSTRACT

The growth of companies in a highly competitive world depends on the superior performance of the development process of their products. The theoretical elements associated to product development management in high-tech companies are systematized in this paper, particularly in the biopharmaceutical industry. The particularities of the product development management in the biotechnological industry are evidenced that are based mainly on the duration and the cost of the development, as well as the regulatory requirements that they affect. It deepens the functions and competencies of the project manager for this type of industry.


REFERENCES

  1. Evens R. Pharma Success in Product Development-Does Biotechnology Change the Paradigm in Product Development and Attrition. The AAPS Journal. 2016;18(1):281-5.

  2. Pisano G. The Evolution of Science-Based Business: Innovating How We Innovate. Boston, MA: Harvard Business School; 2010.

  3. Getz K, Kaitin K. Why Does the Industry Need a Change? En: Peter Schuler and Brendan Buckley, editors. Re-Engineering Clinical Trials: Best Practices for Streamlining Drug Development. New York: Elsevier Press; 2015. p.3-15.

  4. Ernst & Young Global Limited. Biotechnology Industry Report. Beyond borders. Reaching new heights. Basel: Ernst & Young Global Limited; 2015. Disponible en: http://www.ey.com

  5. Raemdonck D, Burns B. Drug Development Project Management En: Scott D, editor. Pharmaceutical and biomedical project management in a changing global environment. Hoboken, New Jersey: John Wiley & Sons, Inc; 2010. p.81-101.

  6. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32(1):40–51. doi: 10.1038/nbt.2786.

  7. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Economics. 2016;47:20-33.

  8. Evens R, Kaitin K. The evolution of biotechnology and its impact on health care. Health Aff. 2015;34:210-219.

  9. Evens RP, Kaitin KI. The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry--mapping biotechnology’s success.Clin Pharmacol Ther 2014;95(5):528-32. doi: 10.1038/clpt.2014.14.

  10. Walsh G. Biopharmaceutical benchmarks. Nature Biotechnology 2014;32(10):992-1000. doi: 10.1038/nbt.3040.

  11. Miller KL, Lanthier M. Innovation in biologic new molecular entities: 1986–2014. Nat Rev Drug Discov 2015;14(2):83. doi: 10.1038/nrd4535.

  12. Lage A. Las funciones de la ciencia en el modelo económico cubano. En: GESYT, editor. La economía del conocimiento y el socialismo: Preguntas y respuestas. 2 ed. La Habana: Editorial Academia; 2015. p.211-44.

  13. Lage A. Conectando la ciencia con la economía: Las palancas del socialismo. En: GESYT, editor. La economía del conocimiento y el socialismo: Preguntas y respuestas. La Habana: Editorial Academia; 2015. p.148-85.

  14. Lage A. Los procesos de dirección en la empresa de alta tecnología. En: GESYT, editor. La economía del conocimiento y el socialismo: Preguntas y respuestas. 2 ed. La Habana: Editorial Academia; 2015. p.268-93.

  15. Babler S. Project leadership for biomedical industries. En: Scott D, editor. Pharmaceutical and biomedical project management in a changing global environment. Hoboken, New Jersey: John Wiley & Sons, Inc; 2010. p.3-31.

  16. ISO 21500:2012. Directrices para la dirección y gestión de proyectos. Ginebra: Secretaría Central de ISO; 2012. Disponible en https://www.iso.org/obp/ui#iso:std:iso:21500:ed-1:v1:es.

  17. Dzierozynski T, Fleming I. Role of Project Management in Quality Planning and Functions Throughout The Product Lifecycle. En: Scott D, editor. Pharmaceutical and biomedical project management in a changing global environment. Hoboken, New Jersey: John Wiley & Sons, Inc; 2010. p.233-50.

  18. Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Discovery Today 2016;21:379-84.

  19. Lage A. La ciencia y la cultura: Las raíces culturales de la productividad. En: GESYT, editor. La economía del conocimiento y el socialismo: Preguntas y respuestas. La Habana: Editorial Academia; 2015. p.66-88.

  20. Lage A. Sociedad del conocimiento y soberanía nacional en el siglo XXI. En: GESYT, editor. La economía del conocimiento y el socialismo: Preguntas y respuestas. La Habana: Editorial Academia; 2015. p.186-210.

  21. Pisano G. Science Business: The promise, the reality, and the future of biotech. Boston, MA: Harvard Business School; 2006.

  22. Owens PK, Raddad E, Miller JW, Stille JR, Olovich KG, Smith NV, et al. A decade of innovation in pharmaceutical R&D: the Chorus model. Nature Reviews. 2015;14:14-28.

  23. Harpum P. Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology. New Jersey: John Wiley & Sons Inc.; 2010.

  24. Kennedy T. The Project Management Function. Pharmaceutical Project Management. Nueva York: Informa Healthcare; 2008.

  25. International Facility Management Association. Space and Project Management Benchmarks, Research Report # 34. Houston, TX: IFMA; 2010.

  26. Scott D. The next wave of managing biomedical. En: Scott D, editor. Pharmaceutical and biomedical project management in a changing global environment. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2010. p.259-372.

  27. David, FR. Strategic implementation. En: David FR, editor. Strategic management: concepts and cases. Boston: Prentice Hall, 2011. p 250-83.

  28. PM Solutions. Project Manager Skills Benchmark. Chads Ford, PA: Project Management Solutions, Inc.; 2015. Disponible en: http://www.pmsolutions.com/reports/Project_Manager_Skills_ Benchmark_2015_Research_Report.pdf.

  29. Khameneh A, Taheri A, Ershadi M. Offering a framework for evaluating the performance of project risk management system. Procedia - Social and Behavioral Sciences. 2016;226:82-90.

  30. Johnson L. Regulatory Strategies and Submissions An International Product Environment. En: Scott D, editor. Pharmaceutical and biomedical project management in a changing global environment. Hoboken, New Jersey: John Wiley & Sons, Inc; 2010. p.251-81.

  31. DiMasi J, Grabowski H, Hansen R. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics. 2016;47:20-33. Disponible en: http://dx.doi. org/10.1016/j.jhealeco.2016.01.012.

  32. Steven S. Managing successful product portfolio creation and R&D pipelines. En: Scott D, editor. Pharmaceutical and biomedical project management in a changing global environment. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2010. p.305-26.

  33. Schuhmacher A, Gassmann O, Hinderet M. Changing R&D models in research-based pharmaceutical companies. J Transl Med. 2016;14:2-11.




2020     |     www.medigraphic.com